{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:49:11Z","timestamp":1788518951988,"version":"build-2803163510"},"reference-count":56,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inflammatory bowel diseases (IBD), comprising Crohn\u2019s disease (CD) and Ulcerative Colitis (UC), are multifactorial disorders characterized by a chronic inflammatory status with the secretion of cytokines and immune mediators. Biologic drugs targeting pro-inflammatory cytokines, such as infliximab, are broadly used in the treatment of IBD patients, but some patients lose responsiveness after an initial success. The research into new biomarkers is crucial for advancing personalized therapies and monitoring the response to biologics. The aim of this single center, observational study is to analyze the relationship between serum levels of 90K\/Mac-2 BP and the response to infliximab, in a cohort of 48 IBD patients (30 CD and 18 UC), enrolled from February 2017 to December 2018. In our IBD cohort, high 90K serum levels were found at baseline in patients who then developed anti-infliximab antibodies at the fifth infusion (22 weeks after the first), becoming non-responders (9.76 \u00b1 4.65 \u00b5g\/mL compared to 6.53 \u00b1 3.29 \u00b5g\/mL in responder patients, p = 0.005). This difference was significant in the total cohort and in CD, but not significant in UC. We then analyzed the relationship between serum levels of 90K, C-reactive protein (CRP), and Fecal calprotectin. A significant positive correlation was found at baseline between 90K and CRP, the most common serum inflammation marker (R = 0.42, p = 0.0032). We concluded that circulating 90K could be considered a new non-invasive biomarker for monitoring the response to infliximab. Furthermore, 90K serum level determination, before the first infliximab infusion, in association with other inflammatory markers such as CRP, could assist in the choice of biologics for the treatment of IBD patients, thereby obviating the need for a drug switch due to loss of response, and so improving clinical practice and patient care.<\/jats:p>","DOI":"10.3390\/ijms24043955","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T02:04:03Z","timestamp":1676513043000},"page":"3955","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["90K\/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4675-2075","authenticated-orcid":false,"given":"Pasqua Letizia","family":"Pesole","sequence":"first","affiliation":[{"name":"National Institute of Gastroenterology\u2014IRCCS, \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-1869","authenticated-orcid":false,"given":"Marina","family":"Liso","sequence":"additional","affiliation":[{"name":"National Institute of Gastroenterology\u2014IRCCS, \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-673X","authenticated-orcid":false,"given":"Rossella","family":"Donghia","sequence":"additional","affiliation":[{"name":"National Institute of Gastroenterology\u2014IRCCS, \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Guerra","sequence":"additional","affiliation":[{"name":"National Institute of Gastroenterology\u2014IRCCS, \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lippolis","sequence":"additional","affiliation":[{"name":"National Institute of Gastroenterology\u2014IRCCS, \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Mastronardi","sequence":"additional","affiliation":[{"name":"National Institute of Gastroenterology\u2014IRCCS, \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-4125","authenticated-orcid":false,"given":"Palma Aurelia","family":"Iacovazzi","sequence":"additional","affiliation":[{"name":"National Institute of Gastroenterology\u2014IRCCS, \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ncpgasthep0528","article-title":"Mechanisms of disease: Pathogenesis of Crohn\u2019s disease and ulcerative colitis","volume":"3","author":"Sartor","year":"2006","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Saez, A., Herrero-Fernandez, B., Gomez-Bris, R., S\u00e1nchez-Martinez, H., and Gonzalez-Granado, J.M. (2023). Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021526"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Saez, A., Gomez-Bris, R., Herrero-Fernandez, B., Mingorance, C., Rius, C., and Gonzalez-Granado, J.M. (2021). Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147618"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.2147\/JIR.S335502","article-title":"Protease-Activated Receptors\u2014Key Regulators of Inflammatory Bowel Diseases Progression","volume":"14","author":"Jacenik","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fimmu.2019.00647","article-title":"Contribution of Non-immune Cells to Activation and Modulation of the Intestinal Inflammation","volume":"10","author":"Curciarello","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ka\u0142u\u017cna, A., Olczyk, P., and Komosi\u0144ska-Vassev, K. (2022). The Role of Innate and Adaptive Immune Cells in the Pathogenesis and Development of the Inflammatory Response in Ulcerative Colitis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11020400"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1031502","DOI":"10.3389\/fnut.2022.1031502","article-title":"Intermediate role of gut microbiota in vitamin B nutrition and its influences on human health","volume":"9","author":"Wan","year":"2022","journal-title":"Front. Nutr."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jarmakiewicz-Czaja, S., Zieli\u0144ska, M., Sokal, A., and Filip, R. (2022). Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update. Genes, 13.","DOI":"10.1155\/2022\/4344905"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hu, Y., Chen, Z., Xu, C., Kan, S., and Chen, D. (2022). Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease. Nutrients, 14.","DOI":"10.3390\/nu14235140"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/13543784.2016.1126247","article-title":"Anti-TNF-\u03b1 therapies for the treatment of Crohn\u2019s disease: The past, present and future","volume":"25","author":"Berns","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/apt.14410","article-title":"Early Drug and Anti-Infliximab Antibody Levels for Prediction of Primary Nonresponse to Infliximab Therapy","volume":"47","author":"Levhar","year":"2018","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing antiTNFalpha therapy: Serum levels of infliximab and adalimumab associate with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, M.R.D., Ballester, M.P., Romero-Gonz\u00e1lez, E., S\u00e1nchez-Pardo, A.M., Marti-Aguado, D., Tosca, J., Suria, C., Ant\u00f3n Ausejo, R., Pascual Moreno, I., and Silvestre, M.D.P. (2022). Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/j.gastrohep.2022.10.021"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Barrau, M., Duprat, M., Veyrard, P., Tournier, Q., Williet, N., Phelip, J.M., Waeckel, L., Cheifetz, A.S., Papamichael, K., and Roblin, X. (2022). A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease. J. Crohn\u2019s Colitis.","DOI":"10.1093\/ecco-jcc\/jjac164"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.cgh.2022.01.019","article-title":"Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease","volume":"20","author":"Mahmoud","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.3748\/wjg.v21.i40.11246","article-title":"Disease monitoring in inflammatory bowel disease","volume":"21","author":"Chang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_21","first-page":"788","article-title":"Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?","volume":"23","author":"Veisman","year":"2021","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1007\/s10620-021-07088-x","article-title":"High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases","volume":"67","author":"Sasson","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2021.02.002","article-title":"Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases","volume":"70","author":"Villemonteix","year":"2021","journal-title":"Biologicals"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3748\/wjg.v28.i13.1380","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place","volume":"28","author":"Truta","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00365521.2022.2108684","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: Implementation, utilization, and barriers in clinical practice in Scandinavia","volume":"58","author":"Jahnsen","year":"2023","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Marquez-Megias, S., Nalda-Molina, R., Sanz-Valero, J., M\u00e1s-Serrano, P., Diaz-Gonzalez, M., Candela-Boix, M.R., and Ramon-Lopez, A. (2022). Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051009"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4103\/sjg.sjg_3_22","article-title":"Therapeutic drug monitoring for biological medications in inflammatory bowel disease","volume":"28","author":"Cogan","year":"2022","journal-title":"Saudi. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1053\/j.gastro.2022.02.014","article-title":"Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives","volume":"162","author":"Irving","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sethi, S., Dias, S., Kumar, A., Blackwell, J., Brookes, M.J., and Segal, J.P. (2022). Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther.","DOI":"10.1111\/apt.17313"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000518755","article-title":"Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?","volume":"7","author":"Shmais","year":"2021","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.gtc.2021.12.007","article-title":"Therapeutic Drug Monitoring of Biologics in Crohn\u2019s Disease","volume":"51","author":"Grossberg","year":"2022","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Desai, D.C., Dherai, A.J., Strik, A., and Mould, D.R. (2022). Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring. J. Clin. Pharmacol.","DOI":"10.1002\/jcph.2189"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Primas, C., Reinisch, W., Panetta, J.C., Eser, A., Mould, D.R., and Dervieux, T. (2022). Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123316"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Buczy\u0144ska, A., and Grzybowska-Chlebowczyk, U. (2022). Prognostic Factors of Biologic Therapy in Pediatric IBD. Children, 9.","DOI":"10.3390\/children9101558"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.17092","article-title":"Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix","volume":"56","author":"Atia","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.dld.2022.07.004","article-title":"Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease\u2014a prospective, multicentre study","volume":"54","author":"Lontai","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study","volume":"16","author":"Smith","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcmgh.2022.03.003","article-title":"Interleukin 1\u03b2 Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor-Independent Ulcerative Colitis","volume":"14","author":"Liso","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_39","first-page":"3005","article-title":"Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer","volume":"46","author":"Iacobelli","year":"1986","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/JLB.3VMR0118-036R","article-title":"Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections","volume":"104","author":"Loimaranta","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1515\/CCLM.2001.155","article-title":"Serum 90K\/Mac-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: A comparison with alpha-fetoprotein","volume":"39","author":"Iacovazzi","year":"2001","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/172460080301800311","article-title":"Are 90K\/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results","volume":"18","author":"Iacovazzi","year":"2003","journal-title":"Int. J. Biol. Markers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41420-021-00469-1","article-title":"Tgf-\u03b21 transcriptionally promotes 90K expression: Possible implications for cancer progression","volume":"7","author":"Grassadonia","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bor, R., Farkas, K., Fabian, A., Balint, A., Milassin, A., Rutka, M., Matuz, M., Nagy, F., Szepes, Z., and Molnar, T. (2017). Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease. PLoS ONE., 12.","DOI":"10.1371\/journal.pone.0172916"},{"key":"ref_45","first-page":"95","article-title":"Serum Galectin 3, Galectin 9 and Galectin 3-Binding Proteins In Patients With Active And Inactive Inflammatory Bowel Disease","volume":"70","author":"Cibor","year":"2019","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gang, X., Xia, Z., Deng, F., Liu, L., Wang, Q., Yu, Y., Wang, F., Zhu, C., Liu, W., and Cheng, Z. (2019). Inducible LGALS3BP\/90K activates antiviral innate immune responses by targeting TRAF6 and TRAF3 complex. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1008002"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Gallo, V., Arienzo, A., Iacobelli, S., Iacobelli, V., and Antonini, G. (2022). Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202205.0125.v1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41420-021-00447-7","article-title":"Lgals3bp suppresses colon inflammation and tumorigenesis through the downregulation of TAK1-NF-\u03baB signaling","volume":"7","author":"Cho","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/00365521.2018.1486882","article-title":"Success and safety of high infliximab trough levels in inflammatory bowel disease","volume":"53","author":"Drobne","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/MIB.0000000000001223","article-title":"Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study","volume":"23","author":"Roblin","year":"2017","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MIB.0000000000000986","article-title":"Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn\u2019s Disease","volume":"23","author":"Roblin","year":"2017","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MEG.0000000000001332","article-title":"Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab","volume":"31","author":"Orfanoudaki","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wagatsuma, K., Yokoyama, Y., and Nakase, H. (2021). Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life, 11.","DOI":"10.3390\/life11121375"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/ibd\/izaa241","article-title":"Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn\u2019s Disease","volume":"27","author":"Colman","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_55","first-page":"1359","article-title":"Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy","volume":"21","author":"Huang","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_56","first-page":"S41-5","article-title":"Serum galectin-3 and galectin-3 binding protein levels in Beh\u00e7et\u2019s disease and their association with disease activity","volume":"25","author":"Lee","year":"2007","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3955\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:37:17Z","timestamp":1760121437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043955"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043955","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}